The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | How the Hodgkin lymphoma treatment landscape is evolving & future directions
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, comments on the evolving treatment landscape for Hodgkin lymphoma, noting that novel therapies and combinations are offering promising results, although a head-to-head comparison is needed to determine which is most effective. Dr Ansell also highlights the differing approaches in North America and Europe. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the environment in Hodgkin lymphoma is really changing rapidly. I think in a good way because we’re getting new therapies, we’re getting new combinations. The challenge is still to work out which patient benefits most from which particular therapy. So I think if you’re in the United States or in North America, nivolumab and AVD chemotherapy is kind of seen as the primary treatment...
I think the environment in Hodgkin lymphoma is really changing rapidly. I think in a good way because we’re getting new therapies, we’re getting new combinations. The challenge is still to work out which patient benefits most from which particular therapy. So I think if you’re in the United States or in North America, nivolumab and AVD chemotherapy is kind of seen as the primary treatment. If you’re in Europe, particularly within the German Hodgkin lymphoma study group, using BrECADD, brentuximab vedotin and a modified escalated BEACOPP regimen really seems to be the primary therapy there. I think both of those combinations are giving very good responses. Both of them have less toxicity than what we had seen with prior regimens. What we really do need at this point now is a head-to-head comparison of BrECADD and nivolumab-AVD, but obviously that’s going to take a randomized trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
